{"id":"W4362619875","doi":"10.1097/hep.0000000000000395","title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","year":2023,"lang":"en","type":"article","venue":"Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University Health Centre; University of Toronto; University Health Network","funders":"Cilag; Janssen Pharmaceuticals; Novartis Pharma; Genentech; Norgine; AOP Orphan; Eisai; Swedish Orphan Biovitrum; Novo Nordisk; Dr. Falk Pharma; Abbott Laboratories; National Institute for Health and Care Research; Pfizer; Moderna; Celgene; BioCryst; Loxo Oncology; Alnylam Pharmaceuticals; Cook Medical; Ipsen; Gilead Sciences; GlaxoSmithKline; U.S. Department of Justice; Allergan; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; NGM Biopharmaceuticals; Amgen; Kowa Company; Exelixis; Sanofi","keywords":"Medicine; Placebo; Randomized controlled trial; Biliary tract; Internal medicine; Gastroenterology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003171877,0.0009738494,0.002650095,0.0004057447,0.0003874643,0.0008727941,0.0005884352,0.00135243,0.004280551],"category_scores_gemma":[0.001728377,0.0005491163,0.00180285,0.0003775152,0.0009174852,0.0008891094,0.0003570688,0.001812542,0.0006357021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004195495,"about_ca_system_score_gemma":0.0009813248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002593108,"about_ca_topic_score_gemma":0.0009649672,"domain_scores_codex":[0.9991127,0.0005099812,0.0000747216,0.0001076622,0.00009446569,0.000100512],"domain_scores_gemma":[0.9984387,0.0004544777,0.0004864574,0.0001418558,0.0001401248,0.0003384816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9579795,0.0124272,0.002357104,0.0008821309,0.001251644,0.00008202036,0.00007999951,0.0002796316,0.006467033,0.00007862676,0.0005396263,0.01757548],"study_design_scores_gemma":[0.8161091,0.1743508,0.006430753,0.00004512383,0.0009001375,0.0001031552,0.00003724633,0.0002837526,0.0009099006,0.00007976236,0.0007320816,0.00001812615],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922907,0.003556321,0.000467645,0.000314967,0.00009762247,0.001705995,0.000482029,0.00008737879,0.000997429],"genre_scores_gemma":[0.9908723,0.002116342,0.001738837,0.0008701686,0.0003554519,0.002438806,0.0006126705,0.00002048629,0.0009749078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004280551,"threshold_uncertainty_score":0.01677471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007566741783277263,"score_gpt":0.2672923729900228,"score_spread":0.2597256312067455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}